ClinicalTrials.gg

Hepatitis D clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 63 studies for Hepatitis D across more than 10 countries. 21 are recruiting or about to start. 39 of them are mainly about Hepatitis D (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Hepatitis D, Chronic too: 95 studies, 28 open.

Status

Completed
22
Recruiting
14
Active, not recruiting
8
Not yet recruiting
6
Status unknown
6
Terminated
3

Phase

Phase 2
18
Phase 3
10
Phase 1
2

Where

United States
15
Italy
13
France
13
Germany
13
Romania
11
Pakistan
10

Who develops what

Add Hepatitis D to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 4 companies, 3 with this as their studies’ main aim; 4 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Vir Biotechnology, Assembly Biosciences and Huahui Health here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
bulevirtideRecent, repeated
Evidence
  • NCT07200908 · Mirum Pharmaceuticals, Inc. · Phase 3 · live · comparator · “Bulevirtide 2 mg and Brelovitug - 300 mg” · registered Sep 2025
  • NCT07142811 · Vir Biotechnology, Inc. · Phase 2 · live · background · “Bulevirtide” · registered Aug 2025
  • NCT07128550 · Vir Biotechnology, Inc. · Phase 3 · live · background · “Bulevirtide” · registered Aug 2025
Gilead Sciences80% of its industry studiesEU: Gilead Sciences (EMA 2020)23 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.tobevibart, elebsiran · Vir Biotechnology, Inc. · Phase 2 registry mapping onlystudied with bulevirtideNCT07142811 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection — primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48 · 100 enrolled
  • Dec 2026 est.tobevibart, elebsiran · Vir Biotechnology, Inc. · Phase 3 registry mapping onlystudied with bulevirtideNCT07128550 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide — primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24 · 150 enrolled
  • 30 Jun 2027 est.brelovitug · Mirum Pharmaceuticals, Inc. · Phase 3 main aimvs bulevirtideNCT07200908 A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) — primary endpoint: Percentage of participants with a composite endpoint of virologic response and ALT normalization · 172 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hepatitis D studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

6studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6, phase 3 first

Who these studies take

Of the 14 Hepatitis D studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stop at 75 or younger. 3 (21%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (14%) take healthy volunteers.

Recruiting studies that take each age, of 14
AgeWomenMen
101 (7%)1 (7%)
1814 (100%)14 (100%)
3014 (100%)14 (100%)
4014 (100%)14 (100%)
5014 (100%)14 (100%)
6514 (100%)14 (100%)
7513 (93%)13 (93%)
8512 (86%)12 (86%)

Across all 63 studies, recruiting or not: 25% stop at 75 or younger and 8% at 65; 17% take children; 0% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 63. Browse all 63 → or search them.